June 20, 2018 + Jessica Di Palo
5 Min read
MTIP has invested in Quanta Dialysis Technologies Ltd., a British company that has developed advanced haemodialysis systems for use in clinics and at home.
Renal failure is a huge clinical problem with over two million patients receiving dialysis on a weekly basis. For these patients, treatment consumes great amounts of their time and can be a real burden on their quality of life. Quanta aims to improve these patients’ lives by simplifying and creating more treatment flexibility while maitaining high treatment quality.
“We are delighted to welcome MTIP as an investor and we are grateful for their support at this critical time as we prepare for market launch”, said John E. Milad, CEO of Quanta.
“Quanta has done an amazing job at creating a technology that directly meets the needs of dialysis patient’s. With Quanta‘s SC+ personal haemodialysis, patients will have a simpler and easier treatment whether that be in their local clinic or at home”, said Dr. Christoph Kausch, Founding Partner and CEO of MTIP.
Bruce Meadows, the MTIP’s Senior Investment Director, added that “Quanta is exactly the type of company in our investment sweet spot. It improves patient’s quality of life, it saves them time and it saves money across the healthcare system.”
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
MTIP Healthcare Clinic 2019
Healthcare clinic 2019
New MTIP investment in Cynerio
New investment in Cynerio
MTIP invests in Lumeon Ltd.
New investment in Lumeon
Magenverkleinerung mit der Handnähmaschine
Nitinotes news paper article
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta
MTIP’s Healthcare Clinic 2018
Healthcare Clinic 2018
Interview with Christoph Kausch in biotechandmoney
New MTIP investment – Nitinotes Series A Round
New investment in Nitinotes
New investment in an Israeli based digital health company TytoCare
New investment in TytoCare
MTIP joins United Nations-supported Principles for Responsible Investments
MTIP signs Principles for Responsible Investments
MTIP invests in Blueprint Genetics
new investment in Blueprint Genetics